To compare the sensitivity to change and the responsiveness to intervention of the PROMIS Pain Interference short forms, Brief Pain Inventory (BPI), 3-item PEG scale, and SF-36 Bodily Pain subscale in a sample of patients with persistent musculoskeletal pain of moderate severity.
P
ain is the most common symptom reported in both the general population and in primary care. 1 Musculoskeletal pain is consistently the most common, disabling, and costly of all pain complaints, accounting for nearly 70 million outpatient visits in the United States each year. [1] [2] [3] The prevalence, associated disability and cost, 1,3-5 large number of ongoing clinical trials, and pressure on clinicians to monitor pain as the "fifth vital sign" 6 all underscore the need for quality patient-reported outcome measurement in pain.
The Patient-Reported Outcomes Measurement Information System (PROMIS) is a National Institutes of Health Common Fund initiative to improve patient-reported outcome measurement. 7, 8 The PROMIS assessment system is based on a comprehensive (ie, physical, mental, social) self-reported health framework composed of many domains. Domains are represented as unidimensional hierarchies of dozens of items, called "item banks," which are scaled using Item Response Theory (IRT). Item banks include many items to represent fully the range of impairment in a given domain. Item banks can be administered adaptively or assembled as static "short forms" and compared meaningfully across populations. Pain outcome domains in the PROMIS assessment system include pain interference, pain severity, and pain behavior.
A critical psychometric property of pain outcome measures, particularly important in clinical settings and longitudinal studies, is their ability to detect change. Clinical change includes both responsiveness to treatment, or the ability of a measure to accurately detect change when it has occurred following a treatment of known efficacy, and sensitivity to change, which is sometimes used synonymously with responsiveness but which does not require a treatment to be present. 9 Studies comparing the responsiveness of legacy measures (ie, older, established measures commonly developed in a classic test theory framework) have found comparable detection of change among pain-specific measures, including ultra-brief (r4 items) measures, but greater responsiveness and sensitivity for painspecific measures versus general health status measures. [10] [11] [12] [13] [14] [15] [16] [17] Shahgholi et al 18 compared the pre-post responsiveness of PROMIS short forms (pain behavior, pain interference, and physical function) to that of legacy measures (Roland-Morris Disability Index, numerical rating scale) in a single-arm vertebroplasty intervention in a sample of 50 patients. Responsiveness was operationalized as a statistically significant change from baseline to 1 month in mean scores and similarity between measures on the categorization of patients into meaningful change groups (improvement, no change, decline) based on whether a participant's change exceeded a criterion of 1.96Â (O2Â SEM). Results indicated that mean score differences between baseline and 1-month assessment points were statistically significant for all PROMIS and legacy measures (P < 0.0001) and that all measures were similar on the percentage of participants categorized into meaningful change groups.
Stepped Care to Optimize Pain Care Effectiveness (SCOPE), 19 a randomized clinical effectiveness trial of optimized analgesic therapy delivered by a collaborative telecare intervention in primary care, incorporated longitudinal assessment of pain severity, interference, and pain-related disability. We sought to assess pain interference measures for sensitivity to change (with respect to a retrospective global anchor item) in the combined control and intervention samples, and responsiveness to treatment (ie, attributable to a multicomponent stepped care intervention provided in the SCOPE trial) compared with a control group. To our knowledge, this is the first study to compare responsiveness of PROMIS and legacy measures in the context of a randomized controlled trial.
METHODS

Measures
PROMIS Pain Interference Short Forms
PROMIS Pain Interference short forms are composed of items from the unidimensional PROMIS Pain Interference item bank, one of 8 PROMIS item banks that were designed to measure physical functioning as a component of overall self-reported health and validated in large clinical and community samples. The PROMIS Pain Interference items are scaled from 1 to 5, with response options "Not at all," "A little bit," "Somewhat," "Quite a bit," and "Very much," respectively. We assessed responsiveness of the 4-item pain interference short form included in the PROMIS-29 Profile instrument, the 8-item pain interference short form included on the PROMIS-57 Profile instrument, and the stand-alone 6-item PROMIS Short Form v1.0-Pain Interference 6b. Short forms rather than adaptively administered item banks were chosen as these were more easily adopted into the study data collection process and may be more feasibly adopted in a diversity of clinical settings. Raw scores were converted to IRT-derived T-scores using the scoring manuals available at http://assessmentcenter.net.
Brief Pain Inventory (BPI)
The BPI is an 11-item pain measure validated initially in cancer populations 20 and later in other clinical populations. 13, 21 The BPI measures 2 domains of pain: a 4-item severity dimension and 7-item interference dimension. Both the BPI severity and interference items are scaled from 0 to 10, with response options at scale point 0 and 10, respectively, of "No pain" and "Pain as bad as you can imagine" for the severity items and of "Does not interfere" and "Interferes completely" for the interference items. We assessed responsiveness of the 4-item severity and the 7-item interference subscales separately and also together as an 11-item total.
PEG Scale
The ultra-brief 3-item PEG measure was derived from the BPI and validated in ambulatory care settings. 22 The PEG includes 1 severity item (average pain) and 2 interference items (enjoyment of life and general activity) and uses the same scales and scoring (ie, mean of item scores) as the BPI.
SF-36 Bodily Pain
The 2-item Bodily Pain subscale of the Medical Outcomes Study SF-36 questionnaire has been validated in a wide range of populations. 23, 24 One item assesses pain interference on a 1-5 scale, with response options "Not at all," "A little bit," "Moderately," "Quite a bit," and "Extremely." The other item assesses pain severity on a 1-6 scale, with response options "None," "Very mild," "Mild," "Moderate," "Severe," and "Very severe." We assessed the responsiveness of the 2 items together, as a scale. Responses are transformed into a 0 -100 score.
Reference Standard: Patient-reported Global Change
A single item assessing patient-reported global change 25 from baseline to the 3-month assessment was used as the reference standard for responsiveness. The item asked, "How would you describe your pain now, compared to how you were when you started in our study?" The item was scaled from 1 to 7, with response options "Much better," "Moderately better," "A little better," "No change," "A little worse," "Moderately worse," and "Much worse," respectively.
Details of the SCOPE trial design and study measures have been published. 19 Briefly, the SCOPE trial enrolled veterans with moderate to severe and persistent musculoskeletal pain from 1 of 5 primary care clinics at the VA Medical Center in Indianapolis. Musculoskeletal pain was defined as regional (joints, limbs, back, neck) or more generalized (fibromyalgia or chronic widespread pain). Nonmusculoskeletal single-site pain syndromes (headache, facial pain, chest pain, abdominal pain) and inflammatory types of arthritis that would be treated with disease-modifying drugs (eg, rheumatoid arthritis) were excluded. Moderate to severe pain was defined as a BPI item score Z5 for either the patient's average or worst pain in the past week. Persistent was defined as pain that continued for Z3 months despite trying at least 1 analgesic medication. The study excluded those who did not speak English, had moderately severe cognitive impairment or psychoses, had a pending pain-related VA or Social Security disability claim, were actively suicidal, had current illicit drug use, or had an anticipated life expectancy of <12 months. The SCOPE study protocol was approved by the Indiana University Institutional Review Board and the VA Research Review Committee.
A total of 250 participants were enrolled in the SCOPE study. The study patients had a mean age of 55.1 years (range, 28-65 y); 83% were men; 77% were white, 19% black, and 4% other race. The mean baseline BPI total pain score was 5.2 (1.8), representing a moderate level of pain. The duration of pain was 1 year or longer in 98% of participants. The results reported here represent the data from the 244 patients who completed both baseline and 3-month assessments.
Analyses
Sensitivity to Change: Standardized Response Means (SRM) and Area Under the Curve (AUC)
SRM are effect size measures of within-group change that are computed by standardizing the difference between mean scores within a group at 2 time points. 26 SRMs compare the average change to the variability in change and thus show the size of the change relative to a unit of 1.0 SD:
Mean T1ÀMean T2 SD of change score SRMs were used as the effect size to measure the magnitude of the sensitivity to change between baseline and 3 months on each scale in each of 3 global change reference groups: those who were worse (global change item categories 5-7), those who were the same (category 4), and those who were better (categories 1-3).
In addition, the ability of the measures to detect any improvement (global change <4) and moderate improvement (global change <3) was investigated using receiver operating characteristic (ROC) analyses. AUC values can range from 0.5 (the same as chance) to 1.0 (perfect discrimination) and are interpreted as the probability of a measure correctly discriminating between patients who have improved and those who have not.
Responsiveness to Intervention: Standardized Effect Size (SES)
SESs are effect size measures of between-group difference of change that are computed by standardizing the difference between change-score means of 2 independent groups 26 : Intervention group mean change Àcontrol group mean change Pooled SD of change SESs were used as the effect size to measure the magnitude of the responsiveness of the scales to the SCOPE collaborative telecare intervention. Primary results of the SCOPE trial showed the intervention was effective in reducing persistent musculoskeletal pain and pain-related functional limitations. 19 Cohen's rule of thumb interpretative guidelines for 2-group standardized mean difference effect sizes (ie, 0.2 is small, 0.5 is medium, and 0.8 is large) 27 were used to assess the magnitude of the effects.
RESULTS
Sensitivity to Change: SRM and AUC Table 1 shows the measure-level sensitivity to change for pain measures in the SCOPE study, including baseline and 3-month scores for each measure and each (ie, Worse, Same, Better) group, the change in scores between baseline and 3 months, the statistical significance of the change between reference (ie Same) and other (Worse, Better) groups, and corresponding SRM values. The independent group t test comparison between groups on the change scores from baseline to 3 months revealed that the Worse group showed statistically significant greater change on all measures relative to the Same group change scores. These t tests showed that the Better group demonstrated statistically significant greater change than the Same group on all BPI variants (Severity, Interference, Total), the PEG scale, the SF-36 Bodily Pain subscale, and the PROMIS Pain Interference Short Form 6b, but not on the PROMIS Profile short forms (Profile-29, Profile-57).
Across all measures, effect size estimates of change (Table 1) for the Same (À 0.38 to 0.38) and Worse (À 0.47 to 0.17) groups were small. In the Better group, effect size estimates for all BPI variants (0.71-0.94), PEG (0.86), and SF-36 Bodily Pain (À 0.71, reverse scaled) were medium to large, whereas effect size estimates for all PROMIS variants were small to medium (0.34-0.51). The overlapping confidence intervals indicate that few differences are statistically significant. Table 2 shows the area under the ROC curve (AUC) for each measure. Consistent with the SRM analysis, all BPI variants and the PEG showed greater responsiveness than all PROMIS variants and the SF-36 Bodily Pain subscale. The responsiveness of BPI variants and the PEG to any global improvement (0.677-0.727) was similar to their responsiveness to moderate improvement (0.694-0.743). The responsiveness to any improvement (0.679) was also similar to that of moderate improvement (0.644) for the SF-36 Bodily Pain subscale, as were the ranges of PROMIS short form AUC values to any (0.562-0.612) and moderate improvement (0.597-0.661). Table 3 shows measure-level responsiveness to intervention for treatment and control groups, including group change and corresponding SES estimates for all pain measures. All BPI variants (0.37-0.42) and the PEG (0.37) were more responsive to the SCOPE intervention than PROMIS variants (0.17-0.28) and the SF-36 Bodily Pain subscale (À 0.25, reverse scaled).
Responsiveness to Intervention: SES
Post Hoc Analyses of Item-level Responsiveness and BPI Rating Scales
Post hoc analyses of sensitivity to change and responsiveness to intervention at the individual item level were undertaken to investigate whether the differences in item content could help explain the measure-level findings. Itemlevel results were generally consistent with the measure-level results (item results available from authors). Across all items, effect size estimates of sensitivity to change for the Same (À 0.36 to 0.41) and Worse (À 0.40 to 0.19) groups ranged between small and medium. In the group that reported overall improvement in pain at 3 months, effect size estimates for all BPI items (0.32-0.92) and SF-36 Bodily Pain (À 0.58 to À 0.66, reverse scaled) generally ranged from medium to large, whereas effect size estimates for all PROMIS items ranged from small to medium (0.16-0.40). Table 4 displays BPI, PROMIS, and SF pain interference short form item content, ordered from most to least similar, to facilitate comparison of item-level sensitivity to change. Comparison of SRM values shows that BPI and SF items were each more sensitive to change than any PROMIS w P-value derived from 2-sided independent t-test comparing change scores between reference (ie, "Same) and other groups. Conceptually similar BPI and SF items were more responsive than corresponding PROMIS items. Table 5 shows item-level responsiveness to intervention for treatment and control groups, including group change and corresponding SES estimates for all items. The intervention effect size ranged from small to medium for all items. However, BPI items (0.11-0.56) were generally more responsive to the SCOPE intervention than PROMIS (À 0.05 to 0.27) and the SF-36 Bodily Pain items (À 0.17 to À 0.25, reverse scaled).
DISCUSSION
Using longitudinal data collected in the SCOPE effectiveness trial, we found that PROMIS Pain Interference short forms were less sensitive to change (with respect to a global retrospective anchor) and less responsive to treatment than BPI severity, interference, total, and PEG scales, especially in the group that demonstrated global improvement. The differences in sensitivity to change and responsiveness to treatment held at the item level, as well, and did not appear to result from content differences between the short forms. The overlapping confidence intervals indicated that few differences were statistically significant, which given the magnitude of the differences in effect size, is likely a function of the size of the study sample. The performance of PROMIS Pain Interference short forms relative to the SF-36 Bodily Pain subscale depended on the outcome: the PROMIS short forms were less sensitive to change than the SF-36 Bodily Pain subscale (ie, SRM analyses using global change categories) but similarly responsive to the SCOPE intervention in both measure-level and item-level analyses (ie, SES analyses using between-group treatment effects). Decreased responsiveness and less sensitivity to change renders measures less capable of registering improvement or decline. The poorer sensitivity to change of PROMIS pain interference measures in the study may be attributable to the duration of the study interview and to the order of presentation of measures. The BPI was administered near the beginning of the 30-45 minute interview, whereas the PROMIS and SF-36 Bodily Pain items were administered near the end of the interview. Respondent fatigue arising from the length of interview overall or the large number of pain items in particular could have led to less discrimination in participants' responses to PROMIS pain items. However, subjects were informed at the beginning of the interview that some questions may seem redundant but was done intentionally for research purposes. Moreover, the respondent burden was similar to that in several previous trials showing comparable responsiveness of pain measures. 13, 14 In addition, the respondent burden in the current study was certainly not greater than that in the item bank validation studies undertaken by the PROMIS group. Perhaps most importantly, the SF-36 Bodily Pain subscale items were adjacent to the PROMIS items near the end of the interview but showed greater sensitivity to change than PROMIS items. It is also important to note that the structure of the interview, in which the global change item fell immediately after PROMIS and SF-36 Bodily Pain items, would seem to promote concordance and, thus, greater sensitivity to change rather than less. Taken together, the interview duration and structure do not appear to be viable explanations for the differences in sensitivity to change found in this study. Although the pain measures in SCOPE were not self-administered bur rather completed by interviewer administration, the available evidence suggests that mode of administration has minimal, if any, effect on the psychometric properties of PROMIS measures. 28 Another potential explanation for differences in sensitivity to change is the possibility of an artifactual relationship based upon similarities between the response structures of the study measures and the reference standard for change. However, the opposite was true: there was a greater degree of association between scores of the global change (7 verbally anchored response options) and the BPI (11 numeric response options anchored only at the tails) despite the similarities between the response structures of the The greater responsiveness to treatment of BPI may have resulted from the use of 2 BPI items (worst pain and average pain) for baseline eligibility and use of the PEG, a 3-item scale derived from the BPI, in the automated symptom monitoring (ASM) in the intervention arm. More responsiveness could arguably be expected in the questionnaire that was used to constrain baseline eligibility. In addition, treatment may have been adjusted to optimize the PEG score and the BPI by virtue of the shared content between the measures, thus optimizing its change relative to other pain scales. In addition, it is possible that the intervention group that received ASM as a part of treatment were "trained" on the 0-10 scale. However, in previous trials where ASM was not done (ie, SCAMP trial) or was done with a 5-item BPI (ie, INCPAD trial), the differences in BPI and non-BPI pain scale responsiveness were subtler than those found in the present study. 29, 30 Nevertheless, we acknowledge that this study was not designed to compare these scales headto-head, with random ordering; thus, the issues considered above render the results somewhat less robust to alternative interpretations.
The poorer responsiveness to treatment of the PROMIS pain interference short forms relative to the BPI, PEG, and SF measures contrast with findings reported by Shahgholi and colleagues. Some degree of difference between studies might be expected between the present study and that by Shahgholi and colleagues as a result of differences in design (randomized, controlled trial vs. consecutive cohort), differences in the type and chronicity of pain (ie, chronic and commonly multisite musculoskeletal pain vs. vertebral fracture), differences in the indicators of change (patient global impression vs. statistical thresholds), and difference in sample size (244 vs. 50). However, it seems more likely that these elements could explain between-study rather than within-study differences.
The data in this study strongly suggest that the unique item content of the BPI (ie, mood, sleep, and walking) does not explain the differences in sensitivity to change and responsiveness to treatment between PROMIS short forms and BPI interference items. All BPI items, not just the unique items (ie, mood, sleep, and walking), had larger SRM values than PROMIS short form items for the clinically improved group. Conceptual differences may be a significant driver of the differences in responsiveness. It may be the case that instruments measuring symptom severity are more responsive to treatment effects than instruments measuring the impact/interference of the symptom on day-to-day activities as the latter are more distal to what is actually changing.
PROMIS pain interference measures were validated in a general population sample augmented with a sample of participants with chronic pain to ensure reporting higher levels of pain. Still, it may be possible that these PROMIS short form items exhibit less heterogeneity of responsiveness in clinical populations. Short forms composed of items that maximize precision of measurement across the full continuum of pain could potentially contribute to a lack of heterogeneity if change occurs in a restricted range of the continuum. Direct item-level comparison of PROMIS, BPI, and SF-36 Bodily Pain content suggests the differences in responsiveness to intervention and sensitivity to change are difficult to attribute to differences in the conceptual targets of items. Special factors about clinical samples might also make a difference in responsiveness: receiving a pain intervention if in a trial; higher rates of important pain comorbidities such depression; pain type, bodily location, or chronicity of pain; and clinical population (eg, primary care, cancer, specialty pain clinics, etc.). It is important to note that the effect sizes reported here are based on small sample sizes and are dependent on the variances of the measures in this particular sample. Interpretation and conclusions about the generalizability of the findings should be made cautiously.
As the detection of sensitivity to change is important for cohort studies, and the detection of responsiveness to treatment is essential for clinical trials, future studies of PROMIS pain interference scales are sorely needed before adoption of these measures as primary research outcomes. Future studies should consider counterbalancing the order of administration of measures and including both static and adaptive item administration. In the future, alternatives to the effect size estimates reported here, such as an SEM-based approach or the assessment of change at the individual level in the context of an IRT model, could be considered.
